access to medicines

DATA EXCLUSIVITY EXPLAINED

India is debating the introduction of data exclusivity in pharmaceuticals, a regulatory protection that can delay the entry of generic drugs even after patent expiry. While the move is projected as a way to attract investment and support innovation, it raises serious concerns for India’s generics-driven pharmaceutical industry and access to affordable medicines. In the absence of any international obligation under WTO-TRIPS, the policy choice involves balancing innovation incentives with public health priorities and preserving India’s role as the pharmacy of the developing world.